TransCode Therapeutics Inc (RNAZ) Actualités

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

TransCode Therapeutics Open Letter to Shareholders

BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology...

Form DEF 14A - Other definitive proxy statements

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

The clinical trial Safety Review Committee (SRC) approved opening of Cohort 2 after review of safety data from...

Form PRE 14A - Other preliminary proxy statements

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology

Patients currently remain on study for continued treatment with TTX-MC138  No significant safety or dose...

Form 8-K - Current report

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Two patients dosed; several additional patients screened for enrollmentTrial to evaluate safety and...

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer

BOSTON, Sept. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology...

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology...

Form 8-K - Current report